Acute Toxicity Following Prostate Radiotherapy Linked to Late Toxicity
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Feb. 12, 2025 -- For patients undergoing prostate radiotherapy, acute toxicity is associated with late toxicity and decrement in quality of life, according to a study published online Jan. 30 in The Lancet Oncology.
John Nikitas, M.D., from the University of California, Los Angeles, and colleagues characterized the relationship between acute and late genitourinary and gastrointestinal toxicity among patients receiving conventionally fractionated or moderately hypofractionated prostate radiotherapy in an individual patient data meta-analysis of randomized phase 3 trials. Six trials, with 6,593 patients (4,248 conventionally fractionated; 2,345 moderately hypofractionated), met all eligibility criteria.
Patients were followed for a median of 72 months. The researchers found an association for acute grade 2 or greater genitourinary toxicity with both late grade 2 or greater genitourinary toxicity and decrement at least twice the minimal clinically important difference (MCID) in urinary quality of life (odds ratios, 2.20 and 1.41, respectively). There was also an association for acute grade 2 or greater gastrointestinal toxicity with both late grade 2 or greater gastrointestinal toxicity and decrement at least twice the MCID in bowel quality of life (odds ratios, 2.53 and 1.52, respectively).
"Further prospective studies are needed to evaluate whether strategies that mitigate the risk of acute toxicity lead to reduced rates of late toxicity and whether early interventions to treat acute toxicity impact rates of late toxicity," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
MicroRNA-Based Germline Signature Predicts RT-Induced Genitourinary Toxicity in Prostate Cancer
FRIDAY, April 18, 2025 -- A biomarker consisting primarily of microRNA-based germline biomarkers (mirSNPs), PROSTOX, is valid for predicting radiotherapy (RT)-induced...
CT Exams in 2023 Projected to Result in 103,000 Future Cancers
THURSDAY, April 17, 2025 -- At current utilization and radiation dose levels, computed tomography (CT) examinations in 2023 were projected to result in about 103,000 future...
Prostate Cancer Screening Program Beneficial in Top Decile of Polygenic Risk Score
MONDAY, April 14, 2025 -- A prostate cancer screening program involving participants in the top decile of risk according to a polygenic risk score identifies clinically...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.